A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients.
Acute kidney injury
Albumin
Chronic dialysis
Dialysis
Intradialytic hypotension
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
09
09
2020
accepted:
16
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Intradialytic hypotension (IDH) is a frequent complication of intermittent hemodialysis (IHD), occurring from 15 to 50% of ambulatory sessions, and is more frequent among hospitalized patients with hypoalbuminemia. IDH limits adequate fluid removal and increases the risk for vascular access thrombosis, early hemodialysis (HD) termination, and mortality. Albumin infusion before and during therapy has been used for treating IDH with the varying results. We evaluated the efficacy of albumin infusion in preventing IDH during IHD in hypoalbuminemic inpatients. A randomized, crossover trial was performed in 65 AKI or ESKD patients with hypoalbuminemia (albumin < 3 g/dl) who required HD during hospitalization. Patients were randomized to receive 100 ml of either 0.9%sodium chloride or 25% albumin intravenously at the initiation of each dialysis. These two solutions were alternated for up to six sessions. Patients' vital signs and ultrafiltration removal rate were recorded every 15 to 30 min during dialysis. IDH was assessed by different definitions reported in the literature. All symptoms associated with a noted hypotensive event as well as interventions during the dialysis were recorded. Sixty-five patients were submitted to 249 sessions; the mean age was 58 ([Formula: see text] 12), and 46 (70%) were male with a mean weight of 76 ([Formula: see text] 18) kg. The presence of IDH was lower during albumin sessions based on all definitions. The hypotension risk was significantly decreased based on the Kidney Disease Outcomes Quality Initiative definition; (15% with NS vs. 7% with albumin, p = 0.002). The lowest intradialytic SBP was significantly worse in patients who received 0.9% sodium chloride than albumin (NS 83 vs. albumin 90 mmHg, p = 0.035). Overall ultrafiltration rate was significantly higher in the albumin therapies [NS - 8.25 ml/kg/h (- 11.18 5.80) vs. 8.27 ml/kg/h (- 12.22 to 5.53) with albumin, p = 0.011]. In hypoalbuminemic patients who need HD, albumin administration before the dialysis results in fewer episodes of hypotension and improves fluid removal. Albumin infusion may be of benefit to improve the safety of HD and achievement of fluid balance in these high-risk patients. ClinicalTrials.gov Identifier: NCT04522635.
Sections du résumé
BACKGROUND
Intradialytic hypotension (IDH) is a frequent complication of intermittent hemodialysis (IHD), occurring from 15 to 50% of ambulatory sessions, and is more frequent among hospitalized patients with hypoalbuminemia. IDH limits adequate fluid removal and increases the risk for vascular access thrombosis, early hemodialysis (HD) termination, and mortality. Albumin infusion before and during therapy has been used for treating IDH with the varying results. We evaluated the efficacy of albumin infusion in preventing IDH during IHD in hypoalbuminemic inpatients.
METHODS
A randomized, crossover trial was performed in 65 AKI or ESKD patients with hypoalbuminemia (albumin < 3 g/dl) who required HD during hospitalization. Patients were randomized to receive 100 ml of either 0.9%sodium chloride or 25% albumin intravenously at the initiation of each dialysis. These two solutions were alternated for up to six sessions. Patients' vital signs and ultrafiltration removal rate were recorded every 15 to 30 min during dialysis. IDH was assessed by different definitions reported in the literature. All symptoms associated with a noted hypotensive event as well as interventions during the dialysis were recorded.
RESULTS
Sixty-five patients were submitted to 249 sessions; the mean age was 58 ([Formula: see text] 12), and 46 (70%) were male with a mean weight of 76 ([Formula: see text] 18) kg. The presence of IDH was lower during albumin sessions based on all definitions. The hypotension risk was significantly decreased based on the Kidney Disease Outcomes Quality Initiative definition; (15% with NS vs. 7% with albumin, p = 0.002). The lowest intradialytic SBP was significantly worse in patients who received 0.9% sodium chloride than albumin (NS 83 vs. albumin 90 mmHg, p = 0.035). Overall ultrafiltration rate was significantly higher in the albumin therapies [NS - 8.25 ml/kg/h (- 11.18 5.80) vs. 8.27 ml/kg/h (- 12.22 to 5.53) with albumin, p = 0.011].
CONCLUSION
In hypoalbuminemic patients who need HD, albumin administration before the dialysis results in fewer episodes of hypotension and improves fluid removal. Albumin infusion may be of benefit to improve the safety of HD and achievement of fluid balance in these high-risk patients. ClinicalTrials.gov Identifier: NCT04522635.
Identifiants
pubmed: 33407747
doi: 10.1186/s13054-020-03441-0
pii: 10.1186/s13054-020-03441-0
pmc: PMC7789619
doi:
Substances chimiques
Albumins
0
Banques de données
ClinicalTrials.gov
['NCT04522635']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States
Références
Am J Kidney Dis. 1999 Jun;33(6):1107-14
pubmed: 10352199
N Engl J Med. 2008 Jul 3;359(1):7-20
pubmed: 18492867
Blood Purif. 2010;29(3):245-51
pubmed: 20016148
Int Urol Nephrol. 2006;38(3-4):701-5
pubmed: 17160633
Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006758
pubmed: 21069691
Acta Anaesthesiol Scand. 2018 Aug;62(7):936-944
pubmed: 29664109
Crit Care. 2016 Jun 09;20(1):140
pubmed: 27277830
J Am Soc Nephrol. 2015 Mar;26(3):724-34
pubmed: 25270068
Kidney Int. 2009 Aug;76(4):422-7
pubmed: 19436332
Artif Organs. 2003 Sep;27(9):772-80
pubmed: 12940898
Crit Care Med. 1982 Oct;10(10):650-2
pubmed: 7116885
Am J Kidney Dis. 2018 Jul;72(1):136-148
pubmed: 29478864
Am J Respir Crit Care Med. 2000 Jul;162(1):197-202
pubmed: 10903241
J Intensive Care Soc. 2017 Nov;18(4):282-288
pubmed: 29123557
Crit Care. 2016 Jun 23;20(1):196
pubmed: 27334608
Hemodial Int. 2009 Jul;13(3):293-300
pubmed: 19469884
Clin J Am Soc Nephrol. 2020 Oct 28;:
pubmed: 33115729
Kidney Int. 2002 Sep;62(3):1075-80
pubmed: 12164893
Crit Care. 2013 Jan 24;17(1):R14
pubmed: 23347825
Nephrol Dial Transplant. 2013 Feb;28(2):430-7
pubmed: 22535635
Am J Nephrol. 2012;36(2):168-74
pubmed: 22846598
Semin Dial. 2009 Sep-Oct;22(5):472-5
pubmed: 19522759
Pilot Feasibility Stud. 2019 May 30;5:72
pubmed: 31161046
Blood Purif. 2018;45(1-3):230-235
pubmed: 29478062
Pediatr Nephrol. 2017 Feb;32(2):341-345
pubmed: 27553912
J Am Soc Nephrol. 2004 Feb;15(2):487-92
pubmed: 14747397
J Hypertens. 2010 Feb;28(2):314-24
pubmed: 19927010